By Emily Harris
People with HIV and a low to moderate traditional risk of cardiovascular disease who took a daily 4-mg dose of pitavastatin reduced their risk of major adverse cardiovascular events by 35% relative to a placebo group, according to interim results from a randomized clinical trial that enrolled nearly 7769 participants across 12 countries.
Read the full article here.